Diabetes, CVD and Heart Failure Learning Event

Join us for a 2-hour non-CE learning event that will connect the dots between cardiovascular disease, diabetes, and heart failure. Learn which of the new medicines for diabetes have positive outcomes for reducing cardiovascular events and hospitalizations in those with heart failure after a relatively short treatment period.

Agenda

12:00 PM CST	Treating Diabetes to Reduce CVD Risk and Improve Patient Outcomes Justin Echouffo Tcheugui, MD, M. Phil., PhD
1:00 PM CST	Heart Failure and Type 2 Diabetes (DM2): Understanding the Relationship and Improving Outcomes Kimberly Cuomo MSN, CRNP, CHFN
2:00 PM CST	Closing

Speakers

Justin Echouffo Tcheugui MD, M. Phil., PhD
Assistant Professor of Medicine, Johns Hopkins University

Kimberly Cuomo MSN, CRNP, CHFN
Heart and Vascular Institute, Johns Hopkins Medicine

Learning Objectives

Treating Diabetes to Reduce CVD Risk and Improve Patient Outcomes

1. Understanding of urgency to treat diabetes in cardiovascular practice settings applying a team-based approach to patient-centered care.
2. Summarize the available medications to treat DM2, reduce CVD risks, and improve patient outcomes.
3. Describe mechanisms of actions, indications, dosing, and adverse reactions for DPP4 Inhibitors, GLP1 agonists, and SGLT2 inhibitors.

Heart Failure and Type 2 Diabetes (DM2): Understanding the Relationship and Improving Outcomes

1. Describe the relationship between heart failure and DM2.
2. Review the pharmacologic management of heart failure in patients with DM2 including renal dose adjustments.
3. Discuss the selection of antihyperglycemic therapies in patients with diabetes and heart failure.
4. Explain the impact of anti-hyperglycemic therapies on cardiovascular outcomes including hospitalization for heart failure.

Sponsors

Thank you to Merck Sharpe & Dohme Corp. and Boehringer Ingelheim Pharmaceuticals, Inc.
and Lilly USA, LLC for supporting this educational event.